+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rheumatoid Arthritis Diagnosis Tests - Global Market Trajectory & Analytics

  • ID: 5139951
  • Report
  • February 2022
  • Region: Global
  • 393 Pages
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Abbott Diagnostics
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genway Biotech, Inc.

Global Rheumatoid Arthritis Diagnosis Tests Market to Reach $766.7 Million by 2026


Rheumatoid Arthritis (RA), a chronic autoimmune disease, causes inflammation in the joints, muscles, connective tissues, fibrous tissues, and tendons causing pain and swelling. The disease is developed when certain cells of the immune system do not work properly and attach the healthy joints. The disease mostly affects the wrists, hands, and feet. In this condition, the body identifies the body tissues as antigens and produces antibodies against them resulting in inflammation. Major symptoms of the disease include swelling, pain, joint stiffness, joint deformity, fever, weight loss, loss of mobility and function, unsteadiness while walking, and weakness. Different types of rheumatoid arthritis are seronegative, seropositive and juvenile idiopathic arthritis. Women are more prone to the disease compared to men and it is common among the age group 40 to 60. The diagnosis of the disease depends on the symptoms, physical examination, x-ray, scan, and blood test results of a patient.

Though the disease can attack at any age its prevalence generally begins in people between 30 to 60 years of age. Females are more two to three times more prone to RA than men. The US had the lowest rate of RA prevalence in the recent past in comparison to the other eight major markets like Australia, the US, Japan, France Italy, Germany, Spain and the UK. The US had an RA prevalence rate of 67% in comparison with the standard 73% rate in the other eight markets. The UK demonstrated the highest prevalence of RA at 84%. Alterations in the population of the U.S are expected to bring an unprecedented increase in the growth of incidence cases of RA in the U.S. till 2027. Physicians in the U.S. are expected to focus heavily on diagnostic processes for RA. Rheumatoid arthritis is better managed when detected early as the inflammation reduction process can be begun early. The clinical demonstration of RA is swelling and redness of joints, pain, swelling and stiffness. Diagnosing the disease involves a physical examination, an array of imaging tests, blood tests and medical history analysis of patients and patient`s families. The diagnosis of RA can be influenced by the challenge of separating the disease from other autoimmune disorders showing similar symptoms. A combination of diagnostic processes including a thorough symptomatic evaluation of the patient, X-ray analysis, blood tests and scans and physical examinations are recommended for the optimal management of this disease.

Amid the COVID-19 crisis, the global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$579.8 Million in the year 2020, is projected to reach a revised size of US$766.7 Million by 2026, growing at a CAGR of 4.8% over the analysis period. Serology Tests, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$561.3 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Monitoring Ra Treatment Efficiency Tests segment is readjusted to a revised 4% CAGR for the next 7-year period. This segment currently accounts for a 31.6% share of the global Rheumatoid Arthritis Diagnosis Tests market.



The U.S. Market is Estimated at $124.3 Million in 2021, While China is Forecast to Reach $113.5 Million by 2026


The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$124.3 Million in the year 2021. The country currently accounts for a 20.66% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$113.5 Million in the year 2026 trailing a CAGR of 6.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$120.4 Million by the close of the analysis period.

Global demographic trends spell opportunities for the rheumatoid arthritis (RA) diagnostic tests market. It is acknowledged that prevalence of RA increases with age, and therefore rising aging population widens the demand for diagnosis tests as well as treatments for RA. Over the course of the next two decades, the proportion of 65+ individuals in the total population is expected to double in countries such as the US, UK and Australia. As per the World Health Organization (WHO), total number of people aged 65-years and above is projected to grow from the existing 605 million to nearly 2 billion by the year 2050. While nearly 89 million people in the US are forecast to be 65-years or above by 2050, around 40% of citizens in Japan are projected to belong to the age group by 2060. While the increase in life expectancy represents one of the greatest achievements of the past century, it also poses a significant challenge for healthcare systems. People might live more years but the average number of healthy years is on a decline given the risk of contracting later life conditions such as dementia. About 55% of global healthcare expenditure is likely to be spent on chronic diseases including cardiovascular diseases, cancer and respiratory diseases.

With advancing age, the incidence of various health ailments increases, necessitating the need for laboratory tests for diagnosing the specific diseases such as RA. Impact of autoimmune diseases such as RA on quality of life and associated high cost of treatments are prompting governments and healthcare providers to encourage preventive care, especially with focus on aging population. The growing aging population is therefore offering continuous opportunities for the autoimmune disease diagnostics market, as with advancing age the incidence of various autoimmune conditions such as RA increases, which results in rise in testing volumes translating to higher demand for testing techniques for RA. As RA is mostly common among the old people, and the geriatric population has been increasing recently, the opportunities in the global rheumatoid arthritis diagnosis test market are expected to be on the rise in the future.

Select Competitors (Total 65 Featured) -

  • Abbott Diagnostics
  • Augurex Life Sciences Corp.
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genway Biotech, Inc.
  • Microdrop LLC (imaware)
  • Qiagen NV
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.
Frequently Asked Questions about the Global Market for Rheumatoid Arthritis Diagnosis Tests

What is the estimated value of the Global Market for Rheumatoid Arthritis Diagnosis Tests?

The Global Market for Rheumatoid Arthritis Diagnosis Tests was estimated to be valued at $579.8 Million in 2020.

What is the growth rate of the Global Market for Rheumatoid Arthritis Diagnosis Tests?

The growth rate of the Global Market for Rheumatoid Arthritis Diagnosis Tests is 4.8%, with an estimated value of $766.7 Million by 2026.

What is the forecasted size of the Global Market for Rheumatoid Arthritis Diagnosis Tests?

The Global Market for Rheumatoid Arthritis Diagnosis Tests is estimated to be worth $766.7 Million by 2026.

Who are the key companies in the Global Market for Rheumatoid Arthritis Diagnosis Tests?

Key companies in the Global Market for Rheumatoid Arthritis Diagnosis Tests include Abbott Diagnostics, Augurex Life Sciences Corp., Beckman Coulter, Inc., Bio Rad Laboratories Inc., Exagen Inc., F. Hoffmann, La Roche Ltd., Genway Biotech, Inc. and Qiagen NV.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Diagnostics
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genway Biotech, Inc.

I. METHODOLOGY


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Rheumatoid Arthritis Diagnosis Tests – Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • A Prelude to Rheumatoid Arthritis
  • Causes and Risk Factors
  • Symptoms
  • Rheumatoid Arthritis Diagnostic Tests
  • Serological Tests
  • Monitoring RA Treatment Efficiency Tests
  • Kidney Function Tests
  • Impact of Covid-19 and a Looming Global Recession
  • Impact of COVID-19 on Rheumatoid Arthritis Diagnostic Tests
  • Global Market Outlook and Prospects
  • Global Rheumatoid Arthritis Diagnostic Tests Market Set to Witness Significant Growth
  • Select RA Diagnostic Tests by Player
  • The US and Europe Dominate the Global Market, Developing Countries to Witness Fastest Growth
  • Competition
  • Recent Market Activity
  • Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Rising Incidence of Rheumatoid Arthritis Propels the Demand for Rheumatoid Arthritis Diagnosis
  • Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
  • Growing Aging Population to Drive the Demand for RA Diagnostic Tests
  • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Increasing Use of Rapid Diagnosis Tests Platform
  • Select List of RA Biomarkers used in Clinical Practice
  • Investigational Biomarkers to Diagnose and Monitor RA
  • New Biomarker Tests to Drive the Market Growth
  • More Specific Biomarker Tests
  • Growing Demand for Multiple Tests
  • Repercussions of Sub Optimal Accuracy in RA Testing Drive the Need for Multiple Tests
  • Recent Advancements in Treatment Methods to Boost Market Growth
  • Uptrend in Healthcare Expenditure Drives Opportunities
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Increase in Number of Hospitals & Diagnostics Centers Augurs Well for Market in Developing Regions
  • Increasing Obesity Levels Underpins Market Growth
  • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
  • Technological Advancements Widen the Capabilities of RA Arthritis Tests
  • A Few of the Recent Launches and Advancements
  • Rapid RA Diagnostic Tests for Obtaining Results in Minutes
  • imaware™ Introduces At-Home Rheumatoid Arthritis Screening Test
  • Swedish Biotech Breaks Barrier to Diagnosis with Rheumatoid Arthritis Test
  • Scipher Medicine® Ties Up with Ambry Genetics® to Bring Precision Medicine Test for Rheumatoid Arthritis to Market
  • A New Blood Test Could to Predict Rheumatoid Arthritis
  • A New Blood Test Could to Predict Rheumatoid Arthritis
  • IPM Launches Innovative Program for Rheumatoid Arthritis

4. GLOBAL MARKET PERSPECTIVE


III. MARKET ANALYSIS

UNITED STATES

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)

CANADA

JAPAN

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)

CHINA

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)

EUROPE

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)

FRANCE

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)

GERMANY

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)

ITALY

UNITED KINGDOM

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)

SPAIN


RUSSIA


REST OF EUROPE

ASIA-PACIFIC

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)

AUSTRALIA

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)

INDIA

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)

SOUTH KOREA


REST OF ASIA-PACIFIC

LATIN AMERICA

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)

ARGENTINA


BRAZIL


MEXICO


REST OF LATIN AMERICA

MIDDLE EAST

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)

IRAN


ISRAEL


SAUDI ARABIA


UNITED ARAB EMIRATES


REST OF MIDDLE EAST

AFRICA

  • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)

IV. COMPETITION

  • Total Companies Profiled: 65
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Diagnostics
  • Augurex Life Sciences Corp.
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genway Biotech, Inc.
  • Microdrop LLC (imaware)
  • Qiagen NV
  • Siemens Healthcare GmbH
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown